J Clin Outcomes Manage
Update on the treatment of hepatitis C genotype 1
Curry MP, Bleibel W
Abstract Objective: To review treatment of hepatitis C viral (HCV) infection genotype 1. Methods: Review of the literature in the context of 4 clinical cases. Results: HCV infection affects over 180 million people worldwide with the majority of individuals exposed to the virus developing chronic infection. The success rate of treatment of HCV genotype 1 has increased over the years with the evolution of therapeutic regimens, including the recent addition of direct-acting antiviral agents (DAAs). The sustained virologic response rate has increased from about 10% with initial treatment regimens to over 75% with triple therapy with a DAA and pegylated interferon/ribavirin combination. In addition, the treatment duration has been shortened without significant reduction in response rate. Adding new drugs to HCV treatment regimen increases the complexity of the treatment algorithms, associated side effects, and cost of the therapy. Conclusion: HCV treatment has significantly changed over the past decades with success rates dramatically increasing. This success is expected to reduce the number of patients infected with HCV and subsequently reduce the prevalence of HCV-induced cirrhosis, liver failure, and hepatocellular carcinoma.
Search the Turner White index to find abstracts of articles published in JCOM.